Individuals Stopping Slimming Jabs Regain Pounds Far More Rapidly Compared to Those on Conventional Diets

Fresh analysis suggests that people who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who halt traditional diet and exercise programs.

Published data in a leading medical journal demonstrates that while overweight people often shed a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such drugs need to be informed of the danger of quick rebound weight gain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.

This pace of regain suggests a reversion to pre-treatment weight in about a year and a half.

Weighing Treatments

The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.

The team point out that individuals who lose weight through dieting typically experience a less rapid weight regain—approximately 100 grams monthly—after stopping.

The Reason for the Fast Rebound

Experts propose the mechanism of the jabs explains the accelerated rebound.

GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.

"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this hormone supplement results in hunger is unsuppressed, making overeating far more likely."

An Ongoing Issue?

Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.

Many experts say that, due to the significant potential of relapse, the therapy should be considered long-term.

This opinion is supported by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," similar to managing conditions like diabetes.

Patient Experiences

Individuals who have discontinued the jabs describe a sudden return of hunger.

"It was like a switch that goes on and you become starving," described one woman.

This difficulty is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.

Significant Use

Survey data show that millions of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.

• Adoption is higher among women than males.
• The 40s and 50s age group shows the highest level of interest.
• A large proportion access the drugs through private healthcare rather than public health services.

Finally, experts stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a magic solution and lasting health benefits relies on combined behavioural changes.